News stories about Hologic (NASDAQ:HOLX) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hologic earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 45.2358088658192 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Worth Watching Stocks in the Spotlight: Hologic, Inc., (NASDAQ: HOLX), Government Properties Income Trust … (globalexportlines.com)
- Global HPV Testing Market Growth Outlook by 2023: Roche Diagnostics, Abbott Laboratories, , Qiagen and Hologic (thefuturetechnologies.com)
- Hologic’s mammography system achieves premarket approval (wbjournal.com)
- FDA approves new Hologic 3Dimensions tomosynthesis technologies (dotmed.com)
- Notable Investor’s Watch List: Hologic, Inc., (NASDAQ: HOLX), Berkshire Hathaway Inc., (NYSE: BRK-B); (tradingnewsnow.com)
Several research firms recently commented on HOLX. Needham & Company LLC reissued a “buy” rating and set a $50.00 price objective (up previously from $48.00) on shares of Hologic in a research note on Tuesday, January 9th. Deutsche Bank lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Friday, January 19th. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 price objective on the stock in a research note on Wednesday, December 20th. Finally, Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a research note on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $47.53.
Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million for the quarter, compared to the consensus estimate of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 earnings per share. research analysts anticipate that Hologic will post 2.25 earnings per share for the current year.
In related news, Director Namal Nawana acquired 6,600 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average cost of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now directly owns 6,954 shares of the company’s stock, valued at $263,417.52. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Allison P. Bebo sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $38.75, for a total transaction of $271,250.00. The disclosure for this sale can be found here. Corporate insiders own 0.79% of the company’s stock.
WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/30/hologic-holx-getting-somewhat-favorable-media-coverage-analysis-finds/1974689.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.